- Coordinator
- Smart Immune, France
- Runs
- 1 June 2023 to 30 November 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190102812
What the project is doing
In the project's own words, from its summary on CORDIS.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used in immunodeficiencies & blood malignancies though costly, hard-to-access & linked to many severe complications. Smart Immune puts forth a high-profile solution to solve this gap: ProTcell platform supplies clinical-grade, allogeneic lymphoid progenitor cells produced in just 7 days ex-vivo. These are made into tolerant polyclonal mature T cells by the patients own thymus in a record <3 months (vs. 15-24 months naturally), & reducing complications since infused in our 1st patient (June 2020).
With strong IP, orphan drug label secured & traction across eminent KOLs in >7 countries, we face a window opportunity. With the EICs support, we pursue the less attractive-to-VCs SCID indication, as part of our Series A, to become a front row T-cell therapy player, with future chimeric antigen receptor (CAR) therapies in mind. We project to treat >40k patients by 2030 & recover a ROI of 5,28 over our target Series A.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Smart Immune | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI